Merck announced on December 19, 2024, that its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies. The two-drug regimen of doravirine/islatravir (DOR/ISL) was evaluated in adults with HIV-1 infection.
The trials included patients who were virologically suppressed on different antiretroviral therapy regimens. DOR/ISL demonstrated non-inferiority to baseline antiretroviral therapy (bART) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF).
These positive results are a significant step towards a potential new treatment option for HIV-1 patients. Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025, reinforcing its commitment to infectious disease research.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.